Cargando…
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumor-suppressive eff...
Autores principales: | Feustel, Kavanya, Falchook, Gerald S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Innovative Healthcare Institute
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390703/ https://www.ncbi.nlm.nih.gov/pubmed/36034581 http://dx.doi.org/10.36401/JIPO-22-1 |
Ejemplares similares
-
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
por: Shailesh, Harshita, et al.
Publicado: (2018) -
Discovery of Potent and Selective Covalent Protein
Arginine Methyltransferase 5 (PRMT5) Inhibitors
por: Lin, Hong, et al.
Publicado: (2019) -
Identification
of a Protein Arginine Methyltransferase
7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023) -
Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells
por: Rasheed, Shayaan, et al.
Publicado: (2023) -
Characterization of protein arginine methyltransferase of TgPRMT5 in Toxoplasma gondii
por: Liu, Min, et al.
Publicado: (2019)